egfr Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Thermo Fisher egfr
    Egfr, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 94/100, based on 1611 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/egfr/product/Thermo Fisher
    Average 94 stars, based on 1611 article reviews
    Price from $9.99 to $1999.99
    egfr - by Bioz Stars, 2021-01
    94/100 stars
      Buy from Supplier

    99
    Millipore anti egfr
    Resistance to Th1 <t>cytokine/trastuzumab-mediated</t> class I restoration and HER2 369-377 -CD8 + T-cell targeting of HER2-expressing cancers by EGF/Heregulin is rescued with inhibition of <t>EGFR</t> and HER3 signaling (A) Effect of EGFR- and HER3-mediated signaling on class I restoration by trastuzumab and Th1 cytokines. Trastuzumab-treated HER2 high BT-474 cells were serum starved and activated with EGF, Heregulin, or both, followed by IFNγ and TNFα treatment. Harvested cells were assessed for HLA-ABC expression by flow cytometry. Results are representative of three experiments, and expressed as mean HLA-ABC MCF ± SEM. (B) Trastuzumab/IFNγ/TNFα-treated HER2 high SK-BR-3 ( left panel ) and BT-474 ( right panel ) cells with or without EGF + Heregulin activation, were subsequently treated with anti-EGFR + anti-HER3 neutralizing or IgG1 isotype control antibodies. Harvested cells were assessed for HLA-ABC expression by flow cytometry. In representative panels, filled traces represent isotype-matched control staining, and open traces represent HLA-ABC staining. Color-coded cell treatments are indicated in the legend. Adjoining results in histograms are representative of three experiments, and expressed as mean HLA-ABC MCF ± SEM; cell treatments are indicated below the histograms. (C) Following treatments indicated in (B) above, CFSE-labeled HER2 high SK-BR-3 cells were co-cultured 1:1 with HER2 369-377 -sensitized CD8 + T cells. Tumor cells were harvested, stained with 7-AAD and FITC:anti-CD8, and CSFE + 7-AAD + CD8 - cells (apoptotic) were assessed by flow cytometry. Results are representative of three experiments, and expressed as % apoptotic tumor cells±SEM ( % lysis ) in co-culture minus background. *p≤0.05, **p
    Anti Egfr, supplied by Millipore, used in various techniques. Bioz Stars score: 99/100, based on 367 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti egfr/product/Millipore
    Average 99 stars, based on 367 article reviews
    Price from $9.99 to $1999.99
    anti egfr - by Bioz Stars, 2021-01
    99/100 stars
      Buy from Supplier

    egfr  (Abcam)
    99
    Abcam egfr
    Resistance to Th1 <t>cytokine/trastuzumab-mediated</t> class I restoration and HER2 369-377 -CD8 + T-cell targeting of HER2-expressing cancers by EGF/Heregulin is rescued with inhibition of <t>EGFR</t> and HER3 signaling (A) Effect of EGFR- and HER3-mediated signaling on class I restoration by trastuzumab and Th1 cytokines. Trastuzumab-treated HER2 high BT-474 cells were serum starved and activated with EGF, Heregulin, or both, followed by IFNγ and TNFα treatment. Harvested cells were assessed for HLA-ABC expression by flow cytometry. Results are representative of three experiments, and expressed as mean HLA-ABC MCF ± SEM. (B) Trastuzumab/IFNγ/TNFα-treated HER2 high SK-BR-3 ( left panel ) and BT-474 ( right panel ) cells with or without EGF + Heregulin activation, were subsequently treated with anti-EGFR + anti-HER3 neutralizing or IgG1 isotype control antibodies. Harvested cells were assessed for HLA-ABC expression by flow cytometry. In representative panels, filled traces represent isotype-matched control staining, and open traces represent HLA-ABC staining. Color-coded cell treatments are indicated in the legend. Adjoining results in histograms are representative of three experiments, and expressed as mean HLA-ABC MCF ± SEM; cell treatments are indicated below the histograms. (C) Following treatments indicated in (B) above, CFSE-labeled HER2 high SK-BR-3 cells were co-cultured 1:1 with HER2 369-377 -sensitized CD8 + T cells. Tumor cells were harvested, stained with 7-AAD and FITC:anti-CD8, and CSFE + 7-AAD + CD8 - cells (apoptotic) were assessed by flow cytometry. Results are representative of three experiments, and expressed as % apoptotic tumor cells±SEM ( % lysis ) in co-culture minus background. *p≤0.05, **p
    Egfr, supplied by Abcam, used in various techniques. Bioz Stars score: 99/100, based on 910 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/egfr/product/Abcam
    Average 99 stars, based on 910 article reviews
    Price from $9.99 to $1999.99
    egfr - by Bioz Stars, 2021-01
    99/100 stars
      Buy from Supplier

    92
    Agilent technologies egfr
    Kaplan Meier curves of disease free survival of risk groups for TNBC patients. The patients were stratified into different risk groups. Two low basal <t>(EGFR≤15%</t> and <t>CK5/6≤50%)</t> risk groups: group 1 (n = 20) with low expressions/values of EGFR (≤15%), CK5/6 (≤50%), Ki-67 (≤50%), pT (≤ 3), and pN (≤ 1), and group 2 (n = 30) with low expressions of EGFR and CK5/6, and any high expressions/values of Ki-67, pT, and pN. Two high basal risk groups: group 3 (n = 106) with single high basal expression (EGFR > 15% or CK5/6 > 50%), and group 4 (n = 36) with double high basal expressions (EGFR > 15% and CK5/6 > 50%).
    Egfr, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 92/100, based on 1139 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/egfr/product/Agilent technologies
    Average 92 stars, based on 1139 article reviews
    Price from $9.99 to $1999.99
    egfr - by Bioz Stars, 2021-01
    92/100 stars
      Buy from Supplier

    97
    Abcam anti egfr
    Kaplan Meier curves of disease free survival of risk groups for TNBC patients. The patients were stratified into different risk groups. Two low basal <t>(EGFR≤15%</t> and <t>CK5/6≤50%)</t> risk groups: group 1 (n = 20) with low expressions/values of EGFR (≤15%), CK5/6 (≤50%), Ki-67 (≤50%), pT (≤ 3), and pN (≤ 1), and group 2 (n = 30) with low expressions of EGFR and CK5/6, and any high expressions/values of Ki-67, pT, and pN. Two high basal risk groups: group 3 (n = 106) with single high basal expression (EGFR > 15% or CK5/6 > 50%), and group 4 (n = 36) with double high basal expressions (EGFR > 15% and CK5/6 > 50%).
    Anti Egfr, supplied by Abcam, used in various techniques. Bioz Stars score: 97/100, based on 488 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti egfr/product/Abcam
    Average 97 stars, based on 488 article reviews
    Price from $9.99 to $1999.99
    anti egfr - by Bioz Stars, 2021-01
    97/100 stars
      Buy from Supplier

    99
    Qiagen therascreen egfr rgq pcr kit
    Kaplan Meier curves of disease free survival of risk groups for TNBC patients. The patients were stratified into different risk groups. Two low basal <t>(EGFR≤15%</t> and <t>CK5/6≤50%)</t> risk groups: group 1 (n = 20) with low expressions/values of EGFR (≤15%), CK5/6 (≤50%), Ki-67 (≤50%), pT (≤ 3), and pN (≤ 1), and group 2 (n = 30) with low expressions of EGFR and CK5/6, and any high expressions/values of Ki-67, pT, and pN. Two high basal risk groups: group 3 (n = 106) with single high basal expression (EGFR > 15% or CK5/6 > 50%), and group 4 (n = 36) with double high basal expressions (EGFR > 15% and CK5/6 > 50%).
    Therascreen Egfr Rgq Pcr Kit, supplied by Qiagen, used in various techniques. Bioz Stars score: 99/100, based on 588 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/therascreen egfr rgq pcr kit/product/Qiagen
    Average 99 stars, based on 588 article reviews
    Price from $9.99 to $1999.99
    therascreen egfr rgq pcr kit - by Bioz Stars, 2021-01
    99/100 stars
      Buy from Supplier

    99
    Cell Signaling Technology Inc egfr
    Kaplan Meier curves of disease free survival of risk groups for TNBC patients. The patients were stratified into different risk groups. Two low basal <t>(EGFR≤15%</t> and <t>CK5/6≤50%)</t> risk groups: group 1 (n = 20) with low expressions/values of EGFR (≤15%), CK5/6 (≤50%), Ki-67 (≤50%), pT (≤ 3), and pN (≤ 1), and group 2 (n = 30) with low expressions of EGFR and CK5/6, and any high expressions/values of Ki-67, pT, and pN. Two high basal risk groups: group 3 (n = 106) with single high basal expression (EGFR > 15% or CK5/6 > 50%), and group 4 (n = 36) with double high basal expressions (EGFR > 15% and CK5/6 > 50%).
    Egfr, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 99/100, based on 5908 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/egfr/product/Cell Signaling Technology Inc
    Average 99 stars, based on 5908 article reviews
    Price from $9.99 to $1999.99
    egfr - by Bioz Stars, 2021-01
    99/100 stars
      Buy from Supplier

    96
    Millipore egfr
    Kaplan Meier curves of disease free survival of risk groups for TNBC patients. The patients were stratified into different risk groups. Two low basal <t>(EGFR≤15%</t> and <t>CK5/6≤50%)</t> risk groups: group 1 (n = 20) with low expressions/values of EGFR (≤15%), CK5/6 (≤50%), Ki-67 (≤50%), pT (≤ 3), and pN (≤ 1), and group 2 (n = 30) with low expressions of EGFR and CK5/6, and any high expressions/values of Ki-67, pT, and pN. Two high basal risk groups: group 3 (n = 106) with single high basal expression (EGFR > 15% or CK5/6 > 50%), and group 4 (n = 36) with double high basal expressions (EGFR > 15% and CK5/6 > 50%).
    Egfr, supplied by Millipore, used in various techniques. Bioz Stars score: 96/100, based on 1033 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/egfr/product/Millipore
    Average 96 stars, based on 1033 article reviews
    Price from $9.99 to $1999.99
    egfr - by Bioz Stars, 2021-01
    96/100 stars
      Buy from Supplier

    99
    Cell Signaling Technology Inc phospho egfr tyr1068
    Kaplan Meier curves of disease free survival of risk groups for TNBC patients. The patients were stratified into different risk groups. Two low basal <t>(EGFR≤15%</t> and <t>CK5/6≤50%)</t> risk groups: group 1 (n = 20) with low expressions/values of EGFR (≤15%), CK5/6 (≤50%), Ki-67 (≤50%), pT (≤ 3), and pN (≤ 1), and group 2 (n = 30) with low expressions of EGFR and CK5/6, and any high expressions/values of Ki-67, pT, and pN. Two high basal risk groups: group 3 (n = 106) with single high basal expression (EGFR > 15% or CK5/6 > 50%), and group 4 (n = 36) with double high basal expressions (EGFR > 15% and CK5/6 > 50%).
    Phospho Egfr Tyr1068, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 99/100, based on 408 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phospho egfr tyr1068/product/Cell Signaling Technology Inc
    Average 99 stars, based on 408 article reviews
    Price from $9.99 to $1999.99
    phospho egfr tyr1068 - by Bioz Stars, 2021-01
    99/100 stars
      Buy from Supplier

    99
    Thermo Fisher anti egfr
    Downregulation of <t>EGFR</t> and <t>p1068EGFR</t> expression by EGCG and IIF treatments in BE(2)-C neuroblastoma cells. Cells were treated with 20 μg/mL EGCG and 10 μM IIF, individually and in combination for 24 h. ( A ) Proteins (50 μg) from total cell lysate were subjected to SDS–PAGE and Western blot analysis of EGFR and p1068EGFR expression after 24 h treatments. Actin was used as a loading control. RT-PCR analysis of EGFR ( B ) and NDRG1 ( C ) in control and treated cells. β-actin was used as a control. The values were normalized to the untreated controls. The results are expressed as the average ± SE of three independent experiments. * p
    Anti Egfr, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 251 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti egfr/product/Thermo Fisher
    Average 99 stars, based on 251 article reviews
    Price from $9.99 to $1999.99
    anti egfr - by Bioz Stars, 2021-01
    99/100 stars
      Buy from Supplier

    89
    Targeted Cell Therapies LLC egfr targeted therapies
    Downregulation of <t>EGFR</t> and <t>p1068EGFR</t> expression by EGCG and IIF treatments in BE(2)-C neuroblastoma cells. Cells were treated with 20 μg/mL EGCG and 10 μM IIF, individually and in combination for 24 h. ( A ) Proteins (50 μg) from total cell lysate were subjected to SDS–PAGE and Western blot analysis of EGFR and p1068EGFR expression after 24 h treatments. Actin was used as a loading control. RT-PCR analysis of EGFR ( B ) and NDRG1 ( C ) in control and treated cells. β-actin was used as a control. The values were normalized to the untreated controls. The results are expressed as the average ± SE of three independent experiments. * p
    Egfr Targeted Therapies, supplied by Targeted Cell Therapies LLC, used in various techniques. Bioz Stars score: 89/100, based on 182 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/egfr targeted therapies/product/Targeted Cell Therapies LLC
    Average 89 stars, based on 182 article reviews
    Price from $9.99 to $1999.99
    egfr targeted therapies - by Bioz Stars, 2021-01
    89/100 stars
      Buy from Supplier

    91
    Affibody egfr expression
    Specificity of 99m <t>Tc-ZEGFR:2377</t> uptake in A431 xenografts and <t>EGFR-expressing</t> organs in mice at 3 h after injection. In the blocked group, receptors were saturated by pre-injection of large excess of non-labeled anti-EGFR antibody cetuximab. The data are presented as average (n=4) and SD.
    Egfr Expression, supplied by Affibody, used in various techniques. Bioz Stars score: 91/100, based on 197 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/egfr expression/product/Affibody
    Average 91 stars, based on 197 article reviews
    Price from $9.99 to $1999.99
    egfr expression - by Bioz Stars, 2021-01
    91/100 stars
      Buy from Supplier

    89
    Affibody anti egfr affibody
    Neck lymph node in normal mouse ( a ). The arrows indicate neck lymph nodes in dissection. H E staining showed lymph nodes in the excised cervical tissue ( a ). Two-phase combined imaging of SLNs in normal mice ( b ). 99m Tc-Phytate and <t>anti-EGFR</t> <t>affibody</t> probe were injected into the tongue of mice. Two excised neck specimens with lymph nodes from two mice are shown ( b , left). Autoradiography showed that 99m Tc radioactivity accumulated in the lymph nodes of each neck specimen and one solitary lymph node in the corresponding tissues of the left panel ( b , middle). NIR fluorescence was localized in the lymph nodes after anti-EGFR affibody probe injection into the tongue ( b , right).
    Anti Egfr Affibody, supplied by Affibody, used in various techniques. Bioz Stars score: 89/100, based on 231 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti egfr affibody/product/Affibody
    Average 89 stars, based on 231 article reviews
    Price from $9.99 to $1999.99
    anti egfr affibody - by Bioz Stars, 2021-01
    89/100 stars
      Buy from Supplier

    99
    Thermo Fisher gene exp egfr hs01076078 m1
    <t>Egfr</t> is a direct target gene of Tcfap2c. ( a ) Loss of Tcfap2c through Cre-mediated excision leads to decreased levels of Egfr RNA (top graph) and protein (lower western blot) in mouse mammary cancer cells (* P
    Gene Exp Egfr Hs01076078 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 205 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gene exp egfr hs01076078 m1/product/Thermo Fisher
    Average 99 stars, based on 205 article reviews
    Price from $9.99 to $1999.99
    gene exp egfr hs01076078 m1 - by Bioz Stars, 2021-01
    99/100 stars
      Buy from Supplier

    99
    Millipore a549 cells
    LXA4 restored ENaC subunits' mRNA expressions in <t>A549</t> cells challenged by LPS. (a) LXA4 rescued ENaC-α subunit mRNA expression in A549 cells treated with LPS. The mRNA levels were determined by real-time PCR analysis. The treated groups were Control, LPS (1 μg/ml), LXA4 (100 nmol/L), and in combination. * P = 0.006, LPS versus LPS + LXA4. (b) LXA4 restored EnaC-γ subunit mRNA expression in A549 cells treated with LPS. † P = 0.026, LPS versus LPS + LXA4. LXA4: Lipoxin A4; LPS: Lipopolysaccharide; NDRG1: N-myc downstream-regulated gene 1; ENaC-α: Epithelial sodium channel α subunit; ENaC-γ: Epithelial sodium channel γ subunit; PCR: Polymerase chain reaction.
    A549 Cells, supplied by Millipore, used in various techniques. Bioz Stars score: 99/100, based on 3802 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/a549 cells/product/Millipore
    Average 99 stars, based on 3802 article reviews
    Price from $9.99 to $1999.99
    a549 cells - by Bioz Stars, 2021-01
    99/100 stars
      Buy from Supplier

    96
    Abcam p egfr
    LXA4 restored ENaC subunits' mRNA expressions in <t>A549</t> cells challenged by LPS. (a) LXA4 rescued ENaC-α subunit mRNA expression in A549 cells treated with LPS. The mRNA levels were determined by real-time PCR analysis. The treated groups were Control, LPS (1 μg/ml), LXA4 (100 nmol/L), and in combination. * P = 0.006, LPS versus LPS + LXA4. (b) LXA4 restored EnaC-γ subunit mRNA expression in A549 cells treated with LPS. † P = 0.026, LPS versus LPS + LXA4. LXA4: Lipoxin A4; LPS: Lipopolysaccharide; NDRG1: N-myc downstream-regulated gene 1; ENaC-α: Epithelial sodium channel α subunit; ENaC-γ: Epithelial sodium channel γ subunit; PCR: Polymerase chain reaction.
    P Egfr, supplied by Abcam, used in various techniques. Bioz Stars score: 96/100, based on 163 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p egfr/product/Abcam
    Average 96 stars, based on 163 article reviews
    Price from $9.99 to $1999.99
    p egfr - by Bioz Stars, 2021-01
    96/100 stars
      Buy from Supplier

    98
    Cell Signaling Technology Inc epidermal growth factor receptor egfr
    LXA4 restored ENaC subunits' mRNA expressions in <t>A549</t> cells challenged by LPS. (a) LXA4 rescued ENaC-α subunit mRNA expression in A549 cells treated with LPS. The mRNA levels were determined by real-time PCR analysis. The treated groups were Control, LPS (1 μg/ml), LXA4 (100 nmol/L), and in combination. * P = 0.006, LPS versus LPS + LXA4. (b) LXA4 restored EnaC-γ subunit mRNA expression in A549 cells treated with LPS. † P = 0.026, LPS versus LPS + LXA4. LXA4: Lipoxin A4; LPS: Lipopolysaccharide; NDRG1: N-myc downstream-regulated gene 1; ENaC-α: Epithelial sodium channel α subunit; ENaC-γ: Epithelial sodium channel γ subunit; PCR: Polymerase chain reaction.
    Epidermal Growth Factor Receptor Egfr, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 98/100, based on 83 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/epidermal growth factor receptor egfr/product/Cell Signaling Technology Inc
    Average 98 stars, based on 83 article reviews
    Price from $9.99 to $1999.99
    epidermal growth factor receptor egfr - by Bioz Stars, 2021-01
    98/100 stars
      Buy from Supplier

    92
    Amoy Diagnostics egfr mutations
    Determination of cut-off values for <t>EGFR</t> mutations Background EGFR mutations presented in the plasma cfDNA of 112 healthy individuals were evaluated by <t>ARMS-Plus.</t> The cut-off values for L858R and 19del were 5 copies/mL and 2 copies/mL, respectively.
    Egfr Mutations, supplied by Amoy Diagnostics, used in various techniques. Bioz Stars score: 92/100, based on 184 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/egfr mutations/product/Amoy Diagnostics
    Average 92 stars, based on 184 article reviews
    Price from $9.99 to $1999.99
    egfr mutations - by Bioz Stars, 2021-01
    92/100 stars
      Buy from Supplier

    99
    R&D Systems mouse quantikine elisa kits
    Determination of cut-off values for <t>EGFR</t> mutations Background EGFR mutations presented in the plasma cfDNA of 112 healthy individuals were evaluated by <t>ARMS-Plus.</t> The cut-off values for L858R and 19del were 5 copies/mL and 2 copies/mL, respectively.
    Mouse Quantikine Elisa Kits, supplied by R&D Systems, used in various techniques. Bioz Stars score: 99/100, based on 95 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse quantikine elisa kits/product/R&D Systems
    Average 99 stars, based on 95 article reviews
    Price from $9.99 to $1999.99
    mouse quantikine elisa kits - by Bioz Stars, 2021-01
    99/100 stars
      Buy from Supplier

    N/A
    RayBio Human and Mouse Phospho EGFR Y1068 ELISA Kit This assay semi quantitatively measures phosphorylated EGFR Tyr1045 and Total EGFR in lysate samples
      Buy from Supplier

    N/A
    RayBio Human Phospho EGFR S1070 ELISA Kit This assay semi quantitatively measures phosphorylated EGFR Ser1070 in lysate samples
      Buy from Supplier

    N/A
    RayBio Human Phospho EGFR Y1045 ELISA Kit This assay semi quantitatively measures phosphotyrosine EGFR in lysate samples
      Buy from Supplier


    Image Search Results


    Resistance to Th1 cytokine/trastuzumab-mediated class I restoration and HER2 369-377 -CD8 + T-cell targeting of HER2-expressing cancers by EGF/Heregulin is rescued with inhibition of EGFR and HER3 signaling (A) Effect of EGFR- and HER3-mediated signaling on class I restoration by trastuzumab and Th1 cytokines. Trastuzumab-treated HER2 high BT-474 cells were serum starved and activated with EGF, Heregulin, or both, followed by IFNγ and TNFα treatment. Harvested cells were assessed for HLA-ABC expression by flow cytometry. Results are representative of three experiments, and expressed as mean HLA-ABC MCF ± SEM. (B) Trastuzumab/IFNγ/TNFα-treated HER2 high SK-BR-3 ( left panel ) and BT-474 ( right panel ) cells with or without EGF + Heregulin activation, were subsequently treated with anti-EGFR + anti-HER3 neutralizing or IgG1 isotype control antibodies. Harvested cells were assessed for HLA-ABC expression by flow cytometry. In representative panels, filled traces represent isotype-matched control staining, and open traces represent HLA-ABC staining. Color-coded cell treatments are indicated in the legend. Adjoining results in histograms are representative of three experiments, and expressed as mean HLA-ABC MCF ± SEM; cell treatments are indicated below the histograms. (C) Following treatments indicated in (B) above, CFSE-labeled HER2 high SK-BR-3 cells were co-cultured 1:1 with HER2 369-377 -sensitized CD8 + T cells. Tumor cells were harvested, stained with 7-AAD and FITC:anti-CD8, and CSFE + 7-AAD + CD8 - cells (apoptotic) were assessed by flow cytometry. Results are representative of three experiments, and expressed as % apoptotic tumor cells±SEM ( % lysis ) in co-culture minus background. *p≤0.05, **p

    Journal: Cancer immunology research

    Article Title: CD4+ T-helper Type 1 Cytokines and Trastuzumab Facilitate CD8+ T-cell Targeting of HER-2/neu-expressing Cancers

    doi: 10.1158/2326-6066.CIR-14-0208

    Figure Lengend Snippet: Resistance to Th1 cytokine/trastuzumab-mediated class I restoration and HER2 369-377 -CD8 + T-cell targeting of HER2-expressing cancers by EGF/Heregulin is rescued with inhibition of EGFR and HER3 signaling (A) Effect of EGFR- and HER3-mediated signaling on class I restoration by trastuzumab and Th1 cytokines. Trastuzumab-treated HER2 high BT-474 cells were serum starved and activated with EGF, Heregulin, or both, followed by IFNγ and TNFα treatment. Harvested cells were assessed for HLA-ABC expression by flow cytometry. Results are representative of three experiments, and expressed as mean HLA-ABC MCF ± SEM. (B) Trastuzumab/IFNγ/TNFα-treated HER2 high SK-BR-3 ( left panel ) and BT-474 ( right panel ) cells with or without EGF + Heregulin activation, were subsequently treated with anti-EGFR + anti-HER3 neutralizing or IgG1 isotype control antibodies. Harvested cells were assessed for HLA-ABC expression by flow cytometry. In representative panels, filled traces represent isotype-matched control staining, and open traces represent HLA-ABC staining. Color-coded cell treatments are indicated in the legend. Adjoining results in histograms are representative of three experiments, and expressed as mean HLA-ABC MCF ± SEM; cell treatments are indicated below the histograms. (C) Following treatments indicated in (B) above, CFSE-labeled HER2 high SK-BR-3 cells were co-cultured 1:1 with HER2 369-377 -sensitized CD8 + T cells. Tumor cells were harvested, stained with 7-AAD and FITC:anti-CD8, and CSFE + 7-AAD + CD8 - cells (apoptotic) were assessed by flow cytometry. Results are representative of three experiments, and expressed as % apoptotic tumor cells±SEM ( % lysis ) in co-culture minus background. *p≤0.05, **p

    Article Snippet: HER2-expressing cells were treated with the following, either alone or in designated combinations: rhTNFα, rhIFNγ (BD Biosciences), trastuzumab (Genentech), lapatinib (Santa Cruz Biotechnology); rh-EGF (BD Biosciences), rh-Heregulin (Sigma-Aldrich); neutralizing anti-EGFR (LA1) and/or anti-HER3 (H3.105.5) antibodies, or IgG1 isotype control antibody (all Millipore); and neutralizing anti-PD-1 (MIH1 ( )) or IgG1 isotype control (eBiosciences).

    Techniques: Expressing, Inhibition, Flow Cytometry, Cytometry, Activation Assay, Staining, Labeling, Cell Culture, Lysis, Co-Culture Assay

    GGA2 colocalizes and interacts with EGFR in vivo . ( a ) ARPE-19 cells overexpressing GFP-tagged GGA2 were fixed and double immunofluorescence staining was performed using antibodies against EGFR (red) and TGN46, EEA1, or cathepsin D (blue). Arrows and arrowheads indicate colocalization of three signals in the TGN and peripheral structures, respectively. Bar, 20 μm. ( b ) ARPE-19 cells were fixed for triple immunofluorescence analyses using antibodies against Alexa488-EEA1 (green), endogenous GGA2 (red) and EGFR (blue). Arrowheads indicate colocalization of three signals. Bar, 20 μm. ( c ) ARPE-19 cells transfected with siCtrl, siGGA2, or siEGFR were processed for PLA to detect GGA2-EGFR or GGA2-CIMPR interaction (green). Nuclei were stained with DAPI (blue). Bars, 20 μm.

    Journal: Scientific Reports

    Article Title: GGA2 interacts with EGFR cytoplasmic domain to stabilize the receptor expression and promote cell growth

    doi: 10.1038/s41598-018-19542-4

    Figure Lengend Snippet: GGA2 colocalizes and interacts with EGFR in vivo . ( a ) ARPE-19 cells overexpressing GFP-tagged GGA2 were fixed and double immunofluorescence staining was performed using antibodies against EGFR (red) and TGN46, EEA1, or cathepsin D (blue). Arrows and arrowheads indicate colocalization of three signals in the TGN and peripheral structures, respectively. Bar, 20 μm. ( b ) ARPE-19 cells were fixed for triple immunofluorescence analyses using antibodies against Alexa488-EEA1 (green), endogenous GGA2 (red) and EGFR (blue). Arrowheads indicate colocalization of three signals. Bar, 20 μm. ( c ) ARPE-19 cells transfected with siCtrl, siGGA2, or siEGFR were processed for PLA to detect GGA2-EGFR or GGA2-CIMPR interaction (green). Nuclei were stained with DAPI (blue). Bars, 20 μm.

    Article Snippet: For quantification of EGFR signal in GGA2-depleted ARPE-19 cells re-expressing HA-GGA2kd-resi , fixed cells were immunostained with anti-EGFR antibody (Millipore) without permeabilization, and then immunostained with anti-HA antibody following permeabilization.

    Techniques: In Vivo, Double Immunofluorescence Staining, Immunofluorescence, Transfection, Proximity Ligation Assay, Staining

    GGA2-depletion facilitates lysosomal degradation of EGFR via post-Golgi compartments. ( a ) Control (siCtrl) and GGA2-depleted (siGGA2) ARPE-19 cells were pulse-labeled with [ 35 . ( b ) Signals for EGFR were quantified in three experiments and were plotted as means ± SD. Differences between siCtrl and siGGA2 at each time point were identified using Student’s t -test; * P

    Journal: Scientific Reports

    Article Title: GGA2 interacts with EGFR cytoplasmic domain to stabilize the receptor expression and promote cell growth

    doi: 10.1038/s41598-018-19542-4

    Figure Lengend Snippet: GGA2-depletion facilitates lysosomal degradation of EGFR via post-Golgi compartments. ( a ) Control (siCtrl) and GGA2-depleted (siGGA2) ARPE-19 cells were pulse-labeled with [ 35 . ( b ) Signals for EGFR were quantified in three experiments and were plotted as means ± SD. Differences between siCtrl and siGGA2 at each time point were identified using Student’s t -test; * P

    Article Snippet: For quantification of EGFR signal in GGA2-depleted ARPE-19 cells re-expressing HA-GGA2kd-resi , fixed cells were immunostained with anti-EGFR antibody (Millipore) without permeabilization, and then immunostained with anti-HA antibody following permeabilization.

    Techniques: Labeling

    GGA2 VHS-GAT recognizes EGFR juxtamembrane (jxt) region. ( a ) Domain structures of EGFR and GGA2 mutants used in the binding assay are shown. Numbers indicate amino acid sequences of the proteins. N108A mutation site is indicated in VHS-GAT. TMD, transmembrane domain. ( b and c ) HEK293 cells were transfected with GFP tagged with entire cytoplasmic domain of EGFR (cyto), or with its jxt, kinase, or tail region. Cell lysates were mixed with glutathione sepharose and GST-GGA2 VHS-GAT (GST-VG[WT]) or its N108A mutant (GST-VG[NA]). Bound proteins were then eluted and analyzed using SDS-PAGE and immunoblotting with anti-GFP or -CIMPR (only for [b]) antibody as indicated (Ab). ( d .

    Journal: Scientific Reports

    Article Title: GGA2 interacts with EGFR cytoplasmic domain to stabilize the receptor expression and promote cell growth

    doi: 10.1038/s41598-018-19542-4

    Figure Lengend Snippet: GGA2 VHS-GAT recognizes EGFR juxtamembrane (jxt) region. ( a ) Domain structures of EGFR and GGA2 mutants used in the binding assay are shown. Numbers indicate amino acid sequences of the proteins. N108A mutation site is indicated in VHS-GAT. TMD, transmembrane domain. ( b and c ) HEK293 cells were transfected with GFP tagged with entire cytoplasmic domain of EGFR (cyto), or with its jxt, kinase, or tail region. Cell lysates were mixed with glutathione sepharose and GST-GGA2 VHS-GAT (GST-VG[WT]) or its N108A mutant (GST-VG[NA]). Bound proteins were then eluted and analyzed using SDS-PAGE and immunoblotting with anti-GFP or -CIMPR (only for [b]) antibody as indicated (Ab). ( d .

    Article Snippet: For quantification of EGFR signal in GGA2-depleted ARPE-19 cells re-expressing HA-GGA2kd-resi , fixed cells were immunostained with anti-EGFR antibody (Millipore) without permeabilization, and then immunostained with anti-HA antibody following permeabilization.

    Techniques: Binding Assay, Mutagenesis, Transfection, SDS Page

    Simultaneous depletion of GGA1 or GGA3 with GGA2 restores EGFR expression. ( a and b ) ARPE-19 cells were transfected with control (siCtrl), GGA1 (siGGA1), GGA2 (siGGA2), or GGA3 (siGGA3) siRNAs alone, or with a combination of siGGA2 and siGGA1, or siGGA2 and siGGA3 as indicated. Cells were then fixed for immunofluorescence staining with anti-EGFR antibody ( a ), or were lysed for western blot analysis with antibodies against EGFR, GGA1, GGA2, GGA3, and GAPDH ( b ). Nuclei were labeled with Hoechst 33342. Bar, 20 μm. ( c . ( d ) ARPE-19 cells transfected with siCtrl, siGGA1, or siGGA3 were used for PLA to detect GGA2-EGFR interaction (green). Nuclei were stained with DAPI (blue). Bar, 20 μm. ( e ) PLA signals/cell were counted and mean values ± SD (n = 575 [siCtrl], n = 482 [siGGA1], and n = 448 [siGGA3]) were plotted. Differences were analyzed by one-way ANOVA ( P

    Journal: Scientific Reports

    Article Title: GGA2 interacts with EGFR cytoplasmic domain to stabilize the receptor expression and promote cell growth

    doi: 10.1038/s41598-018-19542-4

    Figure Lengend Snippet: Simultaneous depletion of GGA1 or GGA3 with GGA2 restores EGFR expression. ( a and b ) ARPE-19 cells were transfected with control (siCtrl), GGA1 (siGGA1), GGA2 (siGGA2), or GGA3 (siGGA3) siRNAs alone, or with a combination of siGGA2 and siGGA1, or siGGA2 and siGGA3 as indicated. Cells were then fixed for immunofluorescence staining with anti-EGFR antibody ( a ), or were lysed for western blot analysis with antibodies against EGFR, GGA1, GGA2, GGA3, and GAPDH ( b ). Nuclei were labeled with Hoechst 33342. Bar, 20 μm. ( c . ( d ) ARPE-19 cells transfected with siCtrl, siGGA1, or siGGA3 were used for PLA to detect GGA2-EGFR interaction (green). Nuclei were stained with DAPI (blue). Bar, 20 μm. ( e ) PLA signals/cell were counted and mean values ± SD (n = 575 [siCtrl], n = 482 [siGGA1], and n = 448 [siGGA3]) were plotted. Differences were analyzed by one-way ANOVA ( P

    Article Snippet: For quantification of EGFR signal in GGA2-depleted ARPE-19 cells re-expressing HA-GGA2kd-resi , fixed cells were immunostained with anti-EGFR antibody (Millipore) without permeabilization, and then immunostained with anti-HA antibody following permeabilization.

    Techniques: Expressing, Transfection, Immunofluorescence, Staining, Western Blot, Labeling, Proximity Ligation Assay

    GGA2-depletion causes a drastic decrease in the EGFR protein expression. ( a . ( b ) Band intensities for EGFR were quantified in three or four experiments and mean values ± standard deviations (SD) were plotted. Differences between each GGA siRNA and siCtrl were analyzed by one-way ANOVA ( P

    Journal: Scientific Reports

    Article Title: GGA2 interacts with EGFR cytoplasmic domain to stabilize the receptor expression and promote cell growth

    doi: 10.1038/s41598-018-19542-4

    Figure Lengend Snippet: GGA2-depletion causes a drastic decrease in the EGFR protein expression. ( a . ( b ) Band intensities for EGFR were quantified in three or four experiments and mean values ± standard deviations (SD) were plotted. Differences between each GGA siRNA and siCtrl were analyzed by one-way ANOVA ( P

    Article Snippet: For quantification of EGFR signal in GGA2-depleted ARPE-19 cells re-expressing HA-GGA2kd-resi , fixed cells were immunostained with anti-EGFR antibody (Millipore) without permeabilization, and then immunostained with anti-HA antibody following permeabilization.

    Techniques: Expressing

    EGF-induced EGFR signaling and cell growth are impaired in GGA2-depleted cells. ( a . ( b ) Increase in the ratio of P-MAPK to MAPK after EGF stimulation was calculated and normalized to the value of siCtrl. Mean (±SD) of three experiments were plotted. Statistical difference between the control and each GGA2 siRNA was identified using Student’s t -test (** P

    Journal: Scientific Reports

    Article Title: GGA2 interacts with EGFR cytoplasmic domain to stabilize the receptor expression and promote cell growth

    doi: 10.1038/s41598-018-19542-4

    Figure Lengend Snippet: EGF-induced EGFR signaling and cell growth are impaired in GGA2-depleted cells. ( a . ( b ) Increase in the ratio of P-MAPK to MAPK after EGF stimulation was calculated and normalized to the value of siCtrl. Mean (±SD) of three experiments were plotted. Statistical difference between the control and each GGA2 siRNA was identified using Student’s t -test (** P

    Article Snippet: For quantification of EGFR signal in GGA2-depleted ARPE-19 cells re-expressing HA-GGA2kd-resi , fixed cells were immunostained with anti-EGFR antibody (Millipore) without permeabilization, and then immunostained with anti-HA antibody following permeabilization.

    Techniques:

    Kaplan Meier curves of disease free survival of risk groups for TNBC patients. The patients were stratified into different risk groups. Two low basal (EGFR≤15% and CK5/6≤50%) risk groups: group 1 (n = 20) with low expressions/values of EGFR (≤15%), CK5/6 (≤50%), Ki-67 (≤50%), pT (≤ 3), and pN (≤ 1), and group 2 (n = 30) with low expressions of EGFR and CK5/6, and any high expressions/values of Ki-67, pT, and pN. Two high basal risk groups: group 3 (n = 106) with single high basal expression (EGFR > 15% or CK5/6 > 50%), and group 4 (n = 36) with double high basal expressions (EGFR > 15% and CK5/6 > 50%).

    Journal: PLoS ONE

    Article Title: Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers

    doi: 10.1371/journal.pone.0149661

    Figure Lengend Snippet: Kaplan Meier curves of disease free survival of risk groups for TNBC patients. The patients were stratified into different risk groups. Two low basal (EGFR≤15% and CK5/6≤50%) risk groups: group 1 (n = 20) with low expressions/values of EGFR (≤15%), CK5/6 (≤50%), Ki-67 (≤50%), pT (≤ 3), and pN (≤ 1), and group 2 (n = 30) with low expressions of EGFR and CK5/6, and any high expressions/values of Ki-67, pT, and pN. Two high basal risk groups: group 3 (n = 106) with single high basal expression (EGFR > 15% or CK5/6 > 50%), and group 4 (n = 36) with double high basal expressions (EGFR > 15% and CK5/6 > 50%).

    Article Snippet: Immunostaining for CK 5/6, and EGFR was performed using monoclonal antibodies D5/16 B4 for CK5/6 (Dako, Glostrup, Denmark); and 2-18C9 for EGFR (Dako, Glostrup, Denmark).

    Techniques: Expressing

    Immunoreactivity of 69-yr-old patient with T1bN0M0 TNBC. (A) Hematoxylin and Eosin (H E), (B) EGFR ( > 70%), (C) CK5/6 ( > 70%), (D) ER, (E) PR, (F) HER2, (G) Ki-67 ( > 60%), and (H) P53 ( > 90%). The patient was undergone BCT, had 3.8 event free survival and 22.8 months overall survival.

    Journal: PLoS ONE

    Article Title: Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers

    doi: 10.1371/journal.pone.0149661

    Figure Lengend Snippet: Immunoreactivity of 69-yr-old patient with T1bN0M0 TNBC. (A) Hematoxylin and Eosin (H E), (B) EGFR ( > 70%), (C) CK5/6 ( > 70%), (D) ER, (E) PR, (F) HER2, (G) Ki-67 ( > 60%), and (H) P53 ( > 90%). The patient was undergone BCT, had 3.8 event free survival and 22.8 months overall survival.

    Article Snippet: Immunostaining for CK 5/6, and EGFR was performed using monoclonal antibodies D5/16 B4 for CK5/6 (Dako, Glostrup, Denmark); and 2-18C9 for EGFR (Dako, Glostrup, Denmark).

    Techniques:

    Kaplan Meier curves of disease free survival for basal biomarkers. (a) EGFR at cut-off level 15% with log-rank p = 0.0016, (b) time-dependent ROC analysis of EGFR with AUC = 0.723, where cutoff point 15% (red circled), (c) CK5/6 at cut-off level 50% with log-rank p = 0.0066, and (d) the significance of survival difference at different cutoff values for EGFR and CK5/6. The most significant cutoff values were red-circled with 15% for EGFR and 50% for CK5/6.

    Journal: PLoS ONE

    Article Title: Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers

    doi: 10.1371/journal.pone.0149661

    Figure Lengend Snippet: Kaplan Meier curves of disease free survival for basal biomarkers. (a) EGFR at cut-off level 15% with log-rank p = 0.0016, (b) time-dependent ROC analysis of EGFR with AUC = 0.723, where cutoff point 15% (red circled), (c) CK5/6 at cut-off level 50% with log-rank p = 0.0066, and (d) the significance of survival difference at different cutoff values for EGFR and CK5/6. The most significant cutoff values were red-circled with 15% for EGFR and 50% for CK5/6.

    Article Snippet: Immunostaining for CK 5/6, and EGFR was performed using monoclonal antibodies D5/16 B4 for CK5/6 (Dako, Glostrup, Denmark); and 2-18C9 for EGFR (Dako, Glostrup, Denmark).

    Techniques:

    Comparing the standard EGFR PharmDx™ with the modified EGFR PharmDx™ and the highsensitivity EGFR immunostaining

    Journal: International Journal of Clinical and Experimental Pathology

    Article Title: High-sensitivity epidermal growth factor receptor immunostaining for colorectal carcinomas, compared with EGFR PharmDx(TM): A study of diagnostic accuracy

    doi:

    Figure Lengend Snippet: Comparing the standard EGFR PharmDx™ with the modified EGFR PharmDx™ and the highsensitivity EGFR immunostaining

    Article Snippet: Buckley AF, Kakar S. Comparison of the Dako EGFR PharmDx kit and Zymed EGFR antibody for assessment of EGFR status in colorectal adenocarcinoma.

    Techniques: Modification, Immunostaining

    Comparative study of two colon cancer cases using the standard and modified EGFR PharmDx™ and high-sensitivity EGFR immunostaining with DAK-H1-WT and Novolink. (A, D, G) standard EGFR PharmDx™, (B, E, H) modified EGFR PharmDx™

    Journal: International Journal of Clinical and Experimental Pathology

    Article Title: High-sensitivity epidermal growth factor receptor immunostaining for colorectal carcinomas, compared with EGFR PharmDx(TM): A study of diagnostic accuracy

    doi:

    Figure Lengend Snippet: Comparative study of two colon cancer cases using the standard and modified EGFR PharmDx™ and high-sensitivity EGFR immunostaining with DAK-H1-WT and Novolink. (A, D, G) standard EGFR PharmDx™, (B, E, H) modified EGFR PharmDx™

    Article Snippet: Buckley AF, Kakar S. Comparison of the Dako EGFR PharmDx kit and Zymed EGFR antibody for assessment of EGFR status in colorectal adenocarcinoma.

    Techniques: Modification, Immunostaining

    FISH analysis with two different EGFR-specific FISH probes. A , B , C , D : Dako Cytomation FISH probe mix (EGFR: red, CEN7: green), E , F , G , H : ZytoLight SPEC EGFR/CEN7 dual probe (EGFR: green, CEN7: red), (magnification × 630) A , E : balanced disomy, B , F : balanced trisomy, C , G : low amplification, D , H : high amplification.

    Journal: Diagnostic Pathology

    Article Title: Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC

    doi: 10.1186/s13000-014-0165-0

    Figure Lengend Snippet: FISH analysis with two different EGFR-specific FISH probes. A , B , C , D : Dako Cytomation FISH probe mix (EGFR: red, CEN7: green), E , F , G , H : ZytoLight SPEC EGFR/CEN7 dual probe (EGFR: green, CEN7: red), (magnification × 630) A , E : balanced disomy, B , F : balanced trisomy, C , G : low amplification, D , H : high amplification.

    Article Snippet: Scoring with method (B) showed a similar EGFR expression in SCC and ADC for Dako PharmDx and 31G7.

    Techniques: Fluorescence In Situ Hybridization, Amplification

    Immunohistochemical EGFR staining with four different antibodies showing differences in levels of EGFR expression in the same specimen of a squamous cell carcinoma (SSC) (original magnification × 400). (A) Staining intensity with Dako PharmDx 2+, (B) Staining intensity with 31G7 2+, (C) Staining intensity with 2.1E1 3+, (D) Staining intensity with SP84 1+.

    Journal: Diagnostic Pathology

    Article Title: Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC

    doi: 10.1186/s13000-014-0165-0

    Figure Lengend Snippet: Immunohistochemical EGFR staining with four different antibodies showing differences in levels of EGFR expression in the same specimen of a squamous cell carcinoma (SSC) (original magnification × 400). (A) Staining intensity with Dako PharmDx 2+, (B) Staining intensity with 31G7 2+, (C) Staining intensity with 2.1E1 3+, (D) Staining intensity with SP84 1+.

    Article Snippet: Scoring with method (B) showed a similar EGFR expression in SCC and ADC for Dako PharmDx and 31G7.

    Techniques: Immunohistochemistry, Staining, Expressing

    Downregulation of EGFR and p1068EGFR expression by EGCG and IIF treatments in BE(2)-C neuroblastoma cells. Cells were treated with 20 μg/mL EGCG and 10 μM IIF, individually and in combination for 24 h. ( A ) Proteins (50 μg) from total cell lysate were subjected to SDS–PAGE and Western blot analysis of EGFR and p1068EGFR expression after 24 h treatments. Actin was used as a loading control. RT-PCR analysis of EGFR ( B ) and NDRG1 ( C ) in control and treated cells. β-actin was used as a control. The values were normalized to the untreated controls. The results are expressed as the average ± SE of three independent experiments. * p

    Journal: Nutrients

    Article Title: Epigallocatechin-3-gallate and 6-OH-11-O-Hydroxyphenanthrene Limit BE(2)-C Neuroblastoma Cell Growth and Neurosphere Formation In Vitro

    doi: 10.3390/nu10091141

    Figure Lengend Snippet: Downregulation of EGFR and p1068EGFR expression by EGCG and IIF treatments in BE(2)-C neuroblastoma cells. Cells were treated with 20 μg/mL EGCG and 10 μM IIF, individually and in combination for 24 h. ( A ) Proteins (50 μg) from total cell lysate were subjected to SDS–PAGE and Western blot analysis of EGFR and p1068EGFR expression after 24 h treatments. Actin was used as a loading control. RT-PCR analysis of EGFR ( B ) and NDRG1 ( C ) in control and treated cells. β-actin was used as a control. The values were normalized to the untreated controls. The results are expressed as the average ± SE of three independent experiments. * p

    Article Snippet: Antibodies: anti-RARα and anti-RXRγ (Tema Ricerca, Bologna, Italy), anti-EGFR (Thermo Scientific, Waltham, MA, USA), anti-p1068EGFR (Novex, Life Technologies, Carlsbad, CA, USA), anti-Bcl-2 (Sigma-Aldrich, St. Louis, MO, USA), anti-Bax (Applied Biosystem, Monza, Italy) anti-PARP (Santa Cruz Biotechnology, Dallas, TX, USA), anti-COX-2 (Sigma-Aldrich, St. Louis, MO, USA), anti-N-MYC, anti MMP-2, MMP-9, and anti-TIMP-1 (all from Santa Cruz Biotechnology, Dallas, TX, USA), anti-β-tubulin (Sigma-Aldrich, St. Louis, MO, USA), anti-rabbit, and anti-mouse peroxidase conjugated antibodies (GE Healthcare, Milan, Italy).

    Techniques: Expressing, SDS Page, Western Blot, Reverse Transcription Polymerase Chain Reaction

    Schematic representation of correlated EGFRs ( green ) in a cholesterol ( yellow ) enriched lipid domain ( center ) and in a cholesterol-depleted nonraft lipid domain ( right ), drawn to illustrate the conclusion of this study. The red object on EGFR denotes the EGF ligand. Cholesterol molecules increase receptor-receptor interaction and thus promote the stability of correlatively moving EGFRs

    Journal: BMC Biophysics

    Article Title: Exploring in vivo cholesterol-mediated interactions between activated EGF receptors in plasma membrane with single-molecule optical tracking

    doi: 10.1186/s13628-016-0030-5

    Figure Lengend Snippet: Schematic representation of correlated EGFRs ( green ) in a cholesterol ( yellow ) enriched lipid domain ( center ) and in a cholesterol-depleted nonraft lipid domain ( right ), drawn to illustrate the conclusion of this study. The red object on EGFR denotes the EGF ligand. Cholesterol molecules increase receptor-receptor interaction and thus promote the stability of correlatively moving EGFRs

    Article Snippet: After a 70–80 % confluence was reached, HeLa and A431 cells were deprived of serum for 24 h, whereas MCF12A cells were deprived of serum for 3 h. To tag EGFRs in the plasma membranes of live cells, anti-EGFR antibody (Thermo Fisher Scientific, Waltham, MA, USA) was first biotinylated.

    Techniques:

    Specificity of 99m Tc-ZEGFR:2377 uptake in A431 xenografts and EGFR-expressing organs in mice at 3 h after injection. In the blocked group, receptors were saturated by pre-injection of large excess of non-labeled anti-EGFR antibody cetuximab. The data are presented as average (n=4) and SD.

    Journal: International Journal of Oncology

    Article Title: Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator

    doi: 10.3892/ijo.2016.3721

    Figure Lengend Snippet: Specificity of 99m Tc-ZEGFR:2377 uptake in A431 xenografts and EGFR-expressing organs in mice at 3 h after injection. In the blocked group, receptors were saturated by pre-injection of large excess of non-labeled anti-EGFR antibody cetuximab. The data are presented as average (n=4) and SD.

    Article Snippet: The aim of the present study was to evaluate the feasibility of imaging of EGFR expression with the ZEGFR:2377 affibody molecule labeled with 99m Tc using peptide-based cysteine-containing chelator.

    Techniques: Expressing, Mouse Assay, Injection, Labeling

    Tumor-to-organ ratios of 99m Tc-ZEGFR:2377 in BALB/C nu/nu mice bearing EGFR-expressing A431 xenografts. The data are presented as average (n=4) and SD.

    Journal: International Journal of Oncology

    Article Title: Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator

    doi: 10.3892/ijo.2016.3721

    Figure Lengend Snippet: Tumor-to-organ ratios of 99m Tc-ZEGFR:2377 in BALB/C nu/nu mice bearing EGFR-expressing A431 xenografts. The data are presented as average (n=4) and SD.

    Article Snippet: The aim of the present study was to evaluate the feasibility of imaging of EGFR expression with the ZEGFR:2377 affibody molecule labeled with 99m Tc using peptide-based cysteine-containing chelator.

    Techniques: Mouse Assay, Expressing

    Imaging of EGFR-expressing A431 xenografts in BALB/C nu/nu mice using 99m Tc-ZEGFR:2377 at 3 and 24 h after injection.

    Journal: International Journal of Oncology

    Article Title: Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator

    doi: 10.3892/ijo.2016.3721

    Figure Lengend Snippet: Imaging of EGFR-expressing A431 xenografts in BALB/C nu/nu mice using 99m Tc-ZEGFR:2377 at 3 and 24 h after injection.

    Article Snippet: The aim of the present study was to evaluate the feasibility of imaging of EGFR expression with the ZEGFR:2377 affibody molecule labeled with 99m Tc using peptide-based cysteine-containing chelator.

    Techniques: Imaging, Expressing, Mouse Assay, Injection

    Cellular processing of 99m Tc-ZEGFR:2377 by EGFR-expressing MDA468 (A) and A431(B) cell lines. Cells were incubated with 10 nM 99m Tc-ZEGFR:2377. The data are presented as average (n=3) and SD. Error bars are not seen because they are smaller than point symbols.

    Journal: International Journal of Oncology

    Article Title: Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator

    doi: 10.3892/ijo.2016.3721

    Figure Lengend Snippet: Cellular processing of 99m Tc-ZEGFR:2377 by EGFR-expressing MDA468 (A) and A431(B) cell lines. Cells were incubated with 10 nM 99m Tc-ZEGFR:2377. The data are presented as average (n=3) and SD. Error bars are not seen because they are smaller than point symbols.

    Article Snippet: The aim of the present study was to evaluate the feasibility of imaging of EGFR expression with the ZEGFR:2377 affibody molecule labeled with 99m Tc using peptide-based cysteine-containing chelator.

    Techniques: Expressing, Incubation

    Biodistribution of 99m Tc-ZEGFR:2377 in BALB/C nu/nu mice bearing EGFR-expressing A431 xenografts at 3 and 24 h after injection. The data are presented as average (n=4) and SD.

    Journal: International Journal of Oncology

    Article Title: Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator

    doi: 10.3892/ijo.2016.3721

    Figure Lengend Snippet: Biodistribution of 99m Tc-ZEGFR:2377 in BALB/C nu/nu mice bearing EGFR-expressing A431 xenografts at 3 and 24 h after injection. The data are presented as average (n=4) and SD.

    Article Snippet: The aim of the present study was to evaluate the feasibility of imaging of EGFR expression with the ZEGFR:2377 affibody molecule labeled with 99m Tc using peptide-based cysteine-containing chelator.

    Techniques: Mouse Assay, Expressing, Injection

    In vitro specificity of 99m Tc-ZEGFR:2377 binding to three different EGFR-expressing cell lines. Cells were incubated with 10 nM 99m Tc-ZEGFR:2377. A large molar excess of non-labeled ZEGFR:2377 or cetuximab was used for blocking of receptors. The data are presented as average (n=3–6) and SD.

    Journal: International Journal of Oncology

    Article Title: Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator

    doi: 10.3892/ijo.2016.3721

    Figure Lengend Snippet: In vitro specificity of 99m Tc-ZEGFR:2377 binding to three different EGFR-expressing cell lines. Cells were incubated with 10 nM 99m Tc-ZEGFR:2377. A large molar excess of non-labeled ZEGFR:2377 or cetuximab was used for blocking of receptors. The data are presented as average (n=3–6) and SD.

    Article Snippet: The aim of the present study was to evaluate the feasibility of imaging of EGFR expression with the ZEGFR:2377 affibody molecule labeled with 99m Tc using peptide-based cysteine-containing chelator.

    Techniques: In Vitro, Binding Assay, Expressing, Incubation, Labeling, Blocking Assay

    Neck lymph node in normal mouse ( a ). The arrows indicate neck lymph nodes in dissection. H E staining showed lymph nodes in the excised cervical tissue ( a ). Two-phase combined imaging of SLNs in normal mice ( b ). 99m Tc-Phytate and anti-EGFR affibody probe were injected into the tongue of mice. Two excised neck specimens with lymph nodes from two mice are shown ( b , left). Autoradiography showed that 99m Tc radioactivity accumulated in the lymph nodes of each neck specimen and one solitary lymph node in the corresponding tissues of the left panel ( b , middle). NIR fluorescence was localized in the lymph nodes after anti-EGFR affibody probe injection into the tongue ( b , right).

    Journal: International Journal of Molecular Sciences

    Article Title: Imaging of Metastatic Cancer Cells in Sentinel Lymph Nodes using Affibody Probes and Possibility of a Theranostic Approach

    doi: 10.3390/ijms20020427

    Figure Lengend Snippet: Neck lymph node in normal mouse ( a ). The arrows indicate neck lymph nodes in dissection. H E staining showed lymph nodes in the excised cervical tissue ( a ). Two-phase combined imaging of SLNs in normal mice ( b ). 99m Tc-Phytate and anti-EGFR affibody probe were injected into the tongue of mice. Two excised neck specimens with lymph nodes from two mice are shown ( b , left). Autoradiography showed that 99m Tc radioactivity accumulated in the lymph nodes of each neck specimen and one solitary lymph node in the corresponding tissues of the left panel ( b , middle). NIR fluorescence was localized in the lymph nodes after anti-EGFR affibody probe injection into the tongue ( b , right).

    Article Snippet: Anti-EGFR affibody was dissolved in PBS to a final concentration of 1 mg/mL and was then added dithiothreitol (DTT) to a final concentration of 20 mM at > pH 7.5.

    Techniques: Dissection, Staining, Imaging, Mouse Assay, Injection, Autoradiography, Radioactivity, Fluorescence

    ] ( a ). Thin-layer chromatography (TLC) showed that the fluorescence droplet spots of ICG-conjugated anti-EGFR, anti-HER2 affibody, and IR700-conjugated anti-EGFR affibody (2 µL) stayed at the starting point; in contrast, free ICG and free IR700 ran on the slides ( b ).

    Journal: International Journal of Molecular Sciences

    Article Title: Imaging of Metastatic Cancer Cells in Sentinel Lymph Nodes using Affibody Probes and Possibility of a Theranostic Approach

    doi: 10.3390/ijms20020427

    Figure Lengend Snippet: ] ( a ). Thin-layer chromatography (TLC) showed that the fluorescence droplet spots of ICG-conjugated anti-EGFR, anti-HER2 affibody, and IR700-conjugated anti-EGFR affibody (2 µL) stayed at the starting point; in contrast, free ICG and free IR700 ran on the slides ( b ).

    Article Snippet: Anti-EGFR affibody was dissolved in PBS to a final concentration of 1 mg/mL and was then added dithiothreitol (DTT) to a final concentration of 20 mM at > pH 7.5.

    Techniques: Thin Layer Chromatography, Fluorescence

    Near-infrared (NIR) imaging of cell lines by the addition of affibody probes to conditioned medium ( a , b ). SAS cells showed strong fluorescence signals of anti-EGFR affibody imaging probes ( a , left). SAS cells ( a , middle) expressed higher anti-epidermal growth factor receptor (EGFR) levels than MCF-7 cells ( a , right). SK-BR3 cells showed stronger fluorescence signals in anti-HER2 affibody imaging probes than MDA-MB231 cells ( b ). Histological section study ( c ). Anti-HER2 affibody probe was administered to histological sections of lymph nodes from breast cancer patients. Metastatic cancer cells are shown after hematoxylin and eosin (H E) staining ( c , upper row, left). Human epidermal growth factor receptor 2 (HER2) expression was positive in metastatic cancer cells by immunohistochemical staining ( c , upper row, middle). High-intensity NIR signals from the probe identically corresponded with the area of increased HER2 expression ( c , upper row, right). In the HER2-negative metastatic lymph node section ( c , lower row), immunohistochemical staining for HER2 and NIR signals were not visible in metastatic cancer cells ( c , lower row, middle, right). Scale bar in ( a ): 20 μm. Scale bar in ( c ): 200 μm.

    Journal: International Journal of Molecular Sciences

    Article Title: Imaging of Metastatic Cancer Cells in Sentinel Lymph Nodes using Affibody Probes and Possibility of a Theranostic Approach

    doi: 10.3390/ijms20020427

    Figure Lengend Snippet: Near-infrared (NIR) imaging of cell lines by the addition of affibody probes to conditioned medium ( a , b ). SAS cells showed strong fluorescence signals of anti-EGFR affibody imaging probes ( a , left). SAS cells ( a , middle) expressed higher anti-epidermal growth factor receptor (EGFR) levels than MCF-7 cells ( a , right). SK-BR3 cells showed stronger fluorescence signals in anti-HER2 affibody imaging probes than MDA-MB231 cells ( b ). Histological section study ( c ). Anti-HER2 affibody probe was administered to histological sections of lymph nodes from breast cancer patients. Metastatic cancer cells are shown after hematoxylin and eosin (H E) staining ( c , upper row, left). Human epidermal growth factor receptor 2 (HER2) expression was positive in metastatic cancer cells by immunohistochemical staining ( c , upper row, middle). High-intensity NIR signals from the probe identically corresponded with the area of increased HER2 expression ( c , upper row, right). In the HER2-negative metastatic lymph node section ( c , lower row), immunohistochemical staining for HER2 and NIR signals were not visible in metastatic cancer cells ( c , lower row, middle, right). Scale bar in ( a ): 20 μm. Scale bar in ( c ): 200 μm.

    Article Snippet: Anti-EGFR affibody was dissolved in PBS to a final concentration of 1 mg/mL and was then added dithiothreitol (DTT) to a final concentration of 20 mM at > pH 7.5.

    Techniques: Imaging, Fluorescence, Multiple Displacement Amplification, Staining, Expressing, Immunohistochemistry

    Imaging of metastatic cancer cells in lymph nodes. ( a ) In a mouse lymph node metastasis model, an anti-EGFR affibody probe was injected into the mouse tongue 24 h prior to sacrifice and lymph node dissection. Six lymph nodes were excised; three lymph nodes were highly fluorescent, and the remaining three lymph nodes were not fluorescent. Immunohistochemical staining for EGFR was found in fluorescence-positive lymph nodes (lymph node 2 (R), lymph node 3 (R)). EGFR expression was not visible in the nonfluorescent lymph node (lymph node 2 (L)). ( b ) Two lymph nodes, one from each side of the mouse, were dissected 24 h after anti-EGFR affibody probe injection into the tongue. The indocyanine green (ICG) fluorescence signal was obvious and corresponded to the immunohistochemically stained EGFR expression in the lymph nodes (red circles and arrows). The panel on the right is a magnified view of the two lymph nodes in the left panel of the NIR images.

    Journal: International Journal of Molecular Sciences

    Article Title: Imaging of Metastatic Cancer Cells in Sentinel Lymph Nodes using Affibody Probes and Possibility of a Theranostic Approach

    doi: 10.3390/ijms20020427

    Figure Lengend Snippet: Imaging of metastatic cancer cells in lymph nodes. ( a ) In a mouse lymph node metastasis model, an anti-EGFR affibody probe was injected into the mouse tongue 24 h prior to sacrifice and lymph node dissection. Six lymph nodes were excised; three lymph nodes were highly fluorescent, and the remaining three lymph nodes were not fluorescent. Immunohistochemical staining for EGFR was found in fluorescence-positive lymph nodes (lymph node 2 (R), lymph node 3 (R)). EGFR expression was not visible in the nonfluorescent lymph node (lymph node 2 (L)). ( b ) Two lymph nodes, one from each side of the mouse, were dissected 24 h after anti-EGFR affibody probe injection into the tongue. The indocyanine green (ICG) fluorescence signal was obvious and corresponded to the immunohistochemically stained EGFR expression in the lymph nodes (red circles and arrows). The panel on the right is a magnified view of the two lymph nodes in the left panel of the NIR images.

    Article Snippet: Anti-EGFR affibody was dissolved in PBS to a final concentration of 1 mg/mL and was then added dithiothreitol (DTT) to a final concentration of 20 mM at > pH 7.5.

    Techniques: Imaging, Injection, Dissection, Immunohistochemistry, Staining, Fluorescence, Expressing

    Dynamic imaging study. ( a ) NIR images showed changes in the signal from the anti-EGFR affibody probe in the lymph nodes of a normal control mouse (left). The fluorescence signal intensity was examined at 0.5, 1, 2, 3, 4, 6, and 24 h after the tongue injection in two mice (total four lymph nodes). The peak intensity was observed at one and two hours after the injection (right). The error bar shows the standard deviation. ( b ) The left panels are images of metastatic and nonmetastatic lymph nodes. Weak, almost equal NIR signal intensity was found in two nonmetastatic lymph nodes at 0.5 and 1 h post-injection. The signal intensity almost disappeared at 24 h after the injection (top, left). A high signal intensity remained in the metastatic lymph node (arrow) at 24 h after injection (bottom, left). The time-dependent NIR signal intensity of the anti-EGFR affibody probe is represented as a percentage of the initial signal intensity (30 min). The signal intensity ratio was greater for metastatic lymph nodes than nonmetastatic lymph nodes at 1, 2, 3, and 6 h after the injection (right panel). * p

    Journal: International Journal of Molecular Sciences

    Article Title: Imaging of Metastatic Cancer Cells in Sentinel Lymph Nodes using Affibody Probes and Possibility of a Theranostic Approach

    doi: 10.3390/ijms20020427

    Figure Lengend Snippet: Dynamic imaging study. ( a ) NIR images showed changes in the signal from the anti-EGFR affibody probe in the lymph nodes of a normal control mouse (left). The fluorescence signal intensity was examined at 0.5, 1, 2, 3, 4, 6, and 24 h after the tongue injection in two mice (total four lymph nodes). The peak intensity was observed at one and two hours after the injection (right). The error bar shows the standard deviation. ( b ) The left panels are images of metastatic and nonmetastatic lymph nodes. Weak, almost equal NIR signal intensity was found in two nonmetastatic lymph nodes at 0.5 and 1 h post-injection. The signal intensity almost disappeared at 24 h after the injection (top, left). A high signal intensity remained in the metastatic lymph node (arrow) at 24 h after injection (bottom, left). The time-dependent NIR signal intensity of the anti-EGFR affibody probe is represented as a percentage of the initial signal intensity (30 min). The signal intensity ratio was greater for metastatic lymph nodes than nonmetastatic lymph nodes at 1, 2, 3, and 6 h after the injection (right panel). * p

    Article Snippet: Anti-EGFR affibody was dissolved in PBS to a final concentration of 1 mg/mL and was then added dithiothreitol (DTT) to a final concentration of 20 mM at > pH 7.5.

    Techniques: Imaging, Fluorescence, Injection, Mouse Assay, Standard Deviation

    ( a ) Image of a custom-built illuminator (light emitting diode (LED) emission: peak wavelength, 690 nm). Image of SAS xenograft tumor in the back of a mouse after anti-EGFR affibody photoimmunotherapy (PIT). The image was captured one hour after the probe was injected into the right tumor. The contralateral xenograft tumor served as a control (right). ( b ) The CCK-8 assay showed that the combination of the EGFR affibody IR700 probe and NIR irradiation decreased the survival rate of SAS cells rather than exposure to NIR or the EGFR affibody IR700 probe alone ( p

    Journal: International Journal of Molecular Sciences

    Article Title: Imaging of Metastatic Cancer Cells in Sentinel Lymph Nodes using Affibody Probes and Possibility of a Theranostic Approach

    doi: 10.3390/ijms20020427

    Figure Lengend Snippet: ( a ) Image of a custom-built illuminator (light emitting diode (LED) emission: peak wavelength, 690 nm). Image of SAS xenograft tumor in the back of a mouse after anti-EGFR affibody photoimmunotherapy (PIT). The image was captured one hour after the probe was injected into the right tumor. The contralateral xenograft tumor served as a control (right). ( b ) The CCK-8 assay showed that the combination of the EGFR affibody IR700 probe and NIR irradiation decreased the survival rate of SAS cells rather than exposure to NIR or the EGFR affibody IR700 probe alone ( p

    Article Snippet: Anti-EGFR affibody was dissolved in PBS to a final concentration of 1 mg/mL and was then added dithiothreitol (DTT) to a final concentration of 20 mM at > pH 7.5.

    Techniques: Injection, CCK-8 Assay, Irradiation

    Egfr is a direct target gene of Tcfap2c. ( a ) Loss of Tcfap2c through Cre-mediated excision leads to decreased levels of Egfr RNA (top graph) and protein (lower western blot) in mouse mammary cancer cells (* P

    Journal: Oncogene

    Article Title: The role of Tcfap2c in tumorigenesis and cancer growth in an activated Neu model of mammary carcinogenesis

    doi: 10.1038/onc.2015.59

    Figure Lengend Snippet: Egfr is a direct target gene of Tcfap2c. ( a ) Loss of Tcfap2c through Cre-mediated excision leads to decreased levels of Egfr RNA (top graph) and protein (lower western blot) in mouse mammary cancer cells (* P

    Article Snippet: TaqMan primers and probes (Life Technologies) were used for the following human genes: TFAP2C Hs00231476_m1, EGFR Hs01076078_m1 and GAPDH Hs02758991_g1.

    Techniques: Western Blot

    Loss of Tcfap2c attenuates EGFR expression in mammary cancer. IHC of tumors developing in control and KO mice lack the basal marker CK5 and retain the luminal marker, CK8. Expression of CK5 and CK8 was not significantly different between tumors derived from control (Ctl) and KO mice (CK5, P > 0.1; CK8, P > 0.4). NS, not significant. Neu expression was demonstrated in nearly 100% of tumor cells from both control and KO mice ( P > 0.4). Egfr was found to be significantly decreased in tumors derived from the KO mice relative to control (0.69 vs 1.0, * P

    Journal: Oncogene

    Article Title: The role of Tcfap2c in tumorigenesis and cancer growth in an activated Neu model of mammary carcinogenesis

    doi: 10.1038/onc.2015.59

    Figure Lengend Snippet: Loss of Tcfap2c attenuates EGFR expression in mammary cancer. IHC of tumors developing in control and KO mice lack the basal marker CK5 and retain the luminal marker, CK8. Expression of CK5 and CK8 was not significantly different between tumors derived from control (Ctl) and KO mice (CK5, P > 0.1; CK8, P > 0.4). NS, not significant. Neu expression was demonstrated in nearly 100% of tumor cells from both control and KO mice ( P > 0.4). Egfr was found to be significantly decreased in tumors derived from the KO mice relative to control (0.69 vs 1.0, * P

    Article Snippet: TaqMan primers and probes (Life Technologies) were used for the following human genes: TFAP2C Hs00231476_m1, EGFR Hs01076078_m1 and GAPDH Hs02758991_g1.

    Techniques: Expressing, Immunohistochemistry, Mouse Assay, Marker, Derivative Assay

    Egfr pathway-mediated cell viability through Tcfap2c. Experiments with MMneu-flAP2C cells were used to confirm Tcfap2c-regulated activation of Erk was mediated through activation of Egfr. ( a ) Western blots show that Egf activated P-Erk and PD153035 (PD) blocked activation. ( b ) Relative cell viability was increased 24% by Egf stimulation, whereas, PD153035 treatment reduced relative viability to 41% compared to untreated control cells (* P

    Journal: Oncogene

    Article Title: The role of Tcfap2c in tumorigenesis and cancer growth in an activated Neu model of mammary carcinogenesis

    doi: 10.1038/onc.2015.59

    Figure Lengend Snippet: Egfr pathway-mediated cell viability through Tcfap2c. Experiments with MMneu-flAP2C cells were used to confirm Tcfap2c-regulated activation of Erk was mediated through activation of Egfr. ( a ) Western blots show that Egf activated P-Erk and PD153035 (PD) blocked activation. ( b ) Relative cell viability was increased 24% by Egf stimulation, whereas, PD153035 treatment reduced relative viability to 41% compared to untreated control cells (* P

    Article Snippet: TaqMan primers and probes (Life Technologies) were used for the following human genes: TFAP2C Hs00231476_m1, EGFR Hs01076078_m1 and GAPDH Hs02758991_g1.

    Techniques: Activation Assay, Western Blot

    LXA4 restored ENaC subunits' mRNA expressions in A549 cells challenged by LPS. (a) LXA4 rescued ENaC-α subunit mRNA expression in A549 cells treated with LPS. The mRNA levels were determined by real-time PCR analysis. The treated groups were Control, LPS (1 μg/ml), LXA4 (100 nmol/L), and in combination. * P = 0.006, LPS versus LPS + LXA4. (b) LXA4 restored EnaC-γ subunit mRNA expression in A549 cells treated with LPS. † P = 0.026, LPS versus LPS + LXA4. LXA4: Lipoxin A4; LPS: Lipopolysaccharide; NDRG1: N-myc downstream-regulated gene 1; ENaC-α: Epithelial sodium channel α subunit; ENaC-γ: Epithelial sodium channel γ subunit; PCR: Polymerase chain reaction.

    Journal: Chinese Medical Journal

    Article Title: Lipoxin A4 Ameliorates Lipopolysaccharide-Induced A549 Cell Injury through Upregulation of N-myc Downstream-Regulated Gene-1

    doi: 10.4103/0366-6999.232788

    Figure Lengend Snippet: LXA4 restored ENaC subunits' mRNA expressions in A549 cells challenged by LPS. (a) LXA4 rescued ENaC-α subunit mRNA expression in A549 cells treated with LPS. The mRNA levels were determined by real-time PCR analysis. The treated groups were Control, LPS (1 μg/ml), LXA4 (100 nmol/L), and in combination. * P = 0.006, LPS versus LPS + LXA4. (b) LXA4 restored EnaC-γ subunit mRNA expression in A549 cells treated with LPS. † P = 0.026, LPS versus LPS + LXA4. LXA4: Lipoxin A4; LPS: Lipopolysaccharide; NDRG1: N-myc downstream-regulated gene 1; ENaC-α: Epithelial sodium channel α subunit; ENaC-γ: Epithelial sodium channel γ subunit; PCR: Polymerase chain reaction.

    Article Snippet: For experimental tests, A549 cells were inoculated into 10 cm dishes or 6-well plates and cultured in humidified atmosphere containing 5% CO2 at 37°C for 24 h. As cell confluence reached 80%, A549 cells were further cultured with FBS-free DMEM for 12 h. Then, A549 cells were treated with LPS (Sigma, USA), LXA4 (Sigma), LXA4 receptor (ALX) inhibitor (BOC-2, GenScript, USA), or PI3K inhibitor LY-294002 (Sigma) for 6 h or more time.

    Techniques: Expressing, Real-time Polymerase Chain Reaction, Polymerase Chain Reaction

    LXA4 promoted NDRG1 expression in A549 cells. (a) LXA4 induced NDRG1 expression and alleviated inhibition of LPS. * P

    Journal: Chinese Medical Journal

    Article Title: Lipoxin A4 Ameliorates Lipopolysaccharide-Induced A549 Cell Injury through Upregulation of N-myc Downstream-Regulated Gene-1

    doi: 10.4103/0366-6999.232788

    Figure Lengend Snippet: LXA4 promoted NDRG1 expression in A549 cells. (a) LXA4 induced NDRG1 expression and alleviated inhibition of LPS. * P

    Article Snippet: For experimental tests, A549 cells were inoculated into 10 cm dishes or 6-well plates and cultured in humidified atmosphere containing 5% CO2 at 37°C for 24 h. As cell confluence reached 80%, A549 cells were further cultured with FBS-free DMEM for 12 h. Then, A549 cells were treated with LPS (Sigma, USA), LXA4 (Sigma), LXA4 receptor (ALX) inhibitor (BOC-2, GenScript, USA), or PI3K inhibitor LY-294002 (Sigma) for 6 h or more time.

    Techniques: Expressing, Inhibition

    Determination of cut-off values for EGFR mutations Background EGFR mutations presented in the plasma cfDNA of 112 healthy individuals were evaluated by ARMS-Plus. The cut-off values for L858R and 19del were 5 copies/mL and 2 copies/mL, respectively.

    Journal: Oncotarget

    Article Title: A comparison of ARMS-Plus and droplet digital PCR for detecting EGFR activating mutations in plasma

    doi: 10.18632/oncotarget.22997

    Figure Lengend Snippet: Determination of cut-off values for EGFR mutations Background EGFR mutations presented in the plasma cfDNA of 112 healthy individuals were evaluated by ARMS-Plus. The cut-off values for L858R and 19del were 5 copies/mL and 2 copies/mL, respectively.

    Article Snippet: Detection of EGFR mutations by ARMS PCR and ddPCR Tissue genotyping of 21 types of EGFR mutations with ARMS PCR was conducted using Human EGFR Gene Mutations Fluorescence Polymerase Chain Reaction (PCR) Diagnostic Kit (Amoy Diagnostics Co., Ltd., Xiamen, China) according to the manufacturer’s instructions [ ].

    Techniques:

    Determination of detection limit of ARMS-Plus 3 or 10 corresponding EGFR mutant copies in a background of 20,000 copies wt gDNA were tested by ARMS-Plus, with pure wt gDNA as a negative control. The mutations detected per reaction were plotted with the box chart. Both EGFR 19del 1, 19del 2, and L858R mutations were stably detected by ARMS-Plus. The detection limit of ARMS-Plus is at least 0.015%.

    Journal: Oncotarget

    Article Title: A comparison of ARMS-Plus and droplet digital PCR for detecting EGFR activating mutations in plasma

    doi: 10.18632/oncotarget.22997

    Figure Lengend Snippet: Determination of detection limit of ARMS-Plus 3 or 10 corresponding EGFR mutant copies in a background of 20,000 copies wt gDNA were tested by ARMS-Plus, with pure wt gDNA as a negative control. The mutations detected per reaction were plotted with the box chart. Both EGFR 19del 1, 19del 2, and L858R mutations were stably detected by ARMS-Plus. The detection limit of ARMS-Plus is at least 0.015%.

    Article Snippet: Detection of EGFR mutations by ARMS PCR and ddPCR Tissue genotyping of 21 types of EGFR mutations with ARMS PCR was conducted using Human EGFR Gene Mutations Fluorescence Polymerase Chain Reaction (PCR) Diagnostic Kit (Amoy Diagnostics Co., Ltd., Xiamen, China) according to the manufacturer’s instructions [ ].

    Techniques: Mutagenesis, Negative Control, Stable Transfection

    Correlation between radiological responses and the concentration of EGFR mutant alleles in plasma: a case report of a T+P+ patient (a) Serial CT images of the patient. The diagnosis was made at 2015-10 and responses to gefitinib were evaluated every two months thereafter. (b) Longitudinal monitoring of plasma EGFR 19del concentration using ARMS-Plus.

    Journal: Oncotarget

    Article Title: A comparison of ARMS-Plus and droplet digital PCR for detecting EGFR activating mutations in plasma

    doi: 10.18632/oncotarget.22997

    Figure Lengend Snippet: Correlation between radiological responses and the concentration of EGFR mutant alleles in plasma: a case report of a T+P+ patient (a) Serial CT images of the patient. The diagnosis was made at 2015-10 and responses to gefitinib were evaluated every two months thereafter. (b) Longitudinal monitoring of plasma EGFR 19del concentration using ARMS-Plus.

    Article Snippet: Detection of EGFR mutations by ARMS PCR and ddPCR Tissue genotyping of 21 types of EGFR mutations with ARMS PCR was conducted using Human EGFR Gene Mutations Fluorescence Polymerase Chain Reaction (PCR) Diagnostic Kit (Amoy Diagnostics Co., Ltd., Xiamen, China) according to the manufacturer’s instructions [ ].

    Techniques: Concentration Assay, Mutagenesis